Oversikt over tumorrettede intervensjonsstudier i Norge åpne for inklusjon, versjon N2.1 – Klikk her
EMIT1
EMIT1: Establishment of Molecular profiling for Individual Treatment decisions in Early Breast Cancer. PI: Bjørn Naume.
Intraoperativ strålebehandling av brystkreftpasienter
En kvalitetssikringsstudie (etter Targit studien). PI: Steinar Lundgren.
DBCG RT NATURAL
DGBC NATURAL studien (NBCG21). Delbryst versus ingen bestråling til kvinder ≥ 60 år opereret med brystbevarelse for tidlig brystkræft, et klinisk kontrolleret randomiseret fase III studium.
NEOLETEXE
Presurgical treatment with letrozole and exemestane in postmenopausal patients with ER-positive, locally advanced breast cancer: an intra-patient, cross-over trial. PI: Jürgen Geisler.
OPTIMA
OPTIMA (EMIT2). Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis. Bruk av Prosigna test til adjuvant behandlingsbeslutning. PI: Bjørn Naume.
P53 bryststudien
Treatment of patients with advanced breast cancer harboring TP53 mutations with dose-dense cyclophosphamide, PI: Hans Petter Eikesdal.
EPIK-B3
A phase III, multicenter, randomized, double blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphate and tensin homolog protein (PTEN) loss without PIK3CA mutation. PI Norge: Olav Engebråten, OUS
KATE3
A randomized, multicenter, double-blind, placebo-controlled phase III study of the efficacy and safety of trastuzumab emtasine in combination with atezolizumab or placebo in patients with HER2-positive and PD-L1-positive locally advanced or metastatic breast cancer who have received prior trastuzumab (+/-pertuzumab) and taxane-based therapy (PI: Olav Engebråten)
AXSANA
AXillary Surgery After NeoAdjuvant treatment (PI: Ellen Schlichting)
DESTINYBreast12
An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2 Positive Breast Cancer (PI: Olav Engebråten)
NEOLETRIB
Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole (PI: Jürgen Geiser)
ZEST
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Either Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease (PI: Alina Porojnicu, VV Drammen)
NBCG 